Anzeige
Mehr »
Login
Donnerstag, 24.04.2025 Börsentäglich über 12.000 News von 692 internationalen Medien
Jetzt knallt's an der Börse! Diese Aktie hat das Zeug zum Überflieger!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2AFQL | ISIN: SE0008015259 | Ticker-Symbol: 9IB
Stuttgart
24.04.25
08:11 Uhr
4,370 Euro
-0,010
-0,23 %
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
INFANT BACTERIAL THERAPEUTICS AB Chart 1 Jahr
5-Tage-Chart
INFANT BACTERIAL THERAPEUTICS AB 5-Tage-Chart

Aktuelle News zur INFANT BACTERIAL THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
28.03.Infant Bacterial Therapeutics: IBT is granted Breakthrough Therapy Designation for its Drug Candidate26The U.S. Food and Drug Administration (FDA) has granted a Breakthrough Therapy designation for IBP-9414's potential to reduce gastrointestinal-related mortality. A breakthrough designation is intended...
► Artikel lesen
13.02.Infant Bacterial Therapeutics: Infant Bacterial Therapeutics AB (publ) Year-end report January 1 - December 31, 202440Message from the CEO The scientific literature suggests that benign bacteria of the type found in IBT's drug product IBP-9414 can positively affect the health of premature infants. In 2024, we received...
► Artikel lesen
INFANT BACTERIAL THERAPEUTICS Aktie jetzt für 0€ handeln
20.12.24Infant Bacterial Therapeutics Continues Development of Drug Candidate IBP-9414435IBT received results in August from the largest ever randomized clinical trial in premature infants. During the fall, IBT has continued to review the phase 3 results. Parts of the results have previously...
► Artikel lesen
14.11.24Infant Bacterial Therapeutics: Infant Bacterial Therapeutics AB (publ) Interim report January 1 - September 30, 2024172Message from the CEO This quarter, IBT completed the global Phase 3 clinical trial "The Connection Study" for the drug candidate IBP-9414. On July 8, we reported that the last patient was treated. On...
► Artikel lesen
28.08.24Infant Bacterial Therapeutics: Infant Bacterial Therapeutics AB (publ), Interim report January 1 - June 30, 2024153Message from the CEO IBT has announced the crucial results from the global clinical phase 3 study "The Connection Study" for our drug project IBP-9414 are expected in Q3 2024. On the 8th of July, we...
► Artikel lesen
07.05.24Infant Bacterial Therapeutics: Infant Bacterial Therapeutics AB (publ) Interim report January 1 - March 31, 2024126Message from the CEOIBT has successfully completed the recruitment of infants for our Phase III study (The Connection Study), which is the final clinical trial planned according to the IBP-9414 development...
► Artikel lesen
6 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1